Effects of febuxostat on cardiorenal function in patients with heart failure and hyperuricemia

Effects of febuxostat on cardiorenal function in patients with heart failure and hyperuricemia - EFFECT Study

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000010270

Enrollment

Registered

2013-04-01

Start date

2013-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic heart failure

Interventions

febuxostat conventional therapy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: NYHA class II-IV with hyperuricemia Already receiving standard medical therapies No limit for LVEF Age=20 or more Stable inpatient or outpatient

Exclusion criteria

Exclusion criteria: Contraindication for febuxostat Already receiving medications for hyperuricemia Severe liver dysfunction eGFR<30ml/min/1.73m2 Malignant neoplasm Does not provide IC Essential to give medication for hyperuricemia Others

Design outcomes

Primary

Measure	Time frame
Improvement of eGFR	—

Secondary

Measure	Time frame
Cardiac function Anemia Inflammatory marker Cardiac event	—

Countries

Japan

Contacts

Public ContactTsutomu Yoshikawa

Sakakibara Heart Institute Department of Cardiology

tyoshi@shi.heart.or.jp042-314-3111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026